Search Results - liyanaaratchige+tillekeratne

6 Results

Sort By:

Metabolically stable HDAC inhibitors with trifluoromethylpyruvamide as metal-binding group

Project ID: TECH-2023-25 Background Histone Deacetylases (HDACs) have been studied extensively for their role in regulating expression of genes and proteins involved in cancer cell proliferation and migration. The Zinc Binding Group (ZBG) is an essential component of the HDAC inhibitor pharmacophore. It binds to the zinc ion in the enzyme active...

Novel Ferroptosis Inducers To Treat Cancer

Project ID: D2022-15 Background ferroptosis is a non-apoptotic cell death mechanism impelled by unrestrained accumulation of iron-dependent cellular reactive oxygen (ROS) species leading to membrane lipid peroxidation resulting from intra-cellular antioxidant depletion. Clinical application of ferroptosis agents/drugs has been elusive due to off-target...

Ferroptosis-HDAC Inhibitor Hybrids for treating cancer

Project ID: D2022-16 Background Many cancer treatments target cells and induce apoptosis, a cell death mechanism. Due to genetic instability, tumors become more heterogeneous leading to cells that avert molecular signatures that are targeted by the cancer drugs. Drug resistance remains a major impediment to the success of a cancer treatment. Combinatorial...

Cofilin inhibitor for the treatment of hemorrhagic brain injury-induced inflammation

Project ID D2019-35 Background Cofilin regulates actin filament assembly and organization in most cells, including during macrophage, T-cell, and dendritic activation and migration. Over-activation of cofilin can lead to microglia inflammation in the brain. Although Cofilin has been shown to be involved in the secondary injury of intracerebral hemorrhage...

A new class of HDAC inhibitors with a new metal-binding group

Project ID: D2018-08Background Cancer is group of diseases characterized by uncontrolled growth of abnormal cells. Selectivity towards cancer cells has been challenging, resulting in treatment options with severe side effects. Histone deacetylases (HDAC) are highly expressed in cancer cells and have been investigated for cancer drug development. Out...

Small Drug-like Molecules as Anticancer Agents for NSCLC

Project ID: D2013-04Background Lung cancer is the leading cause of cancer deaths in the United States. More than 80% of the lung cancer deaths belong to non-small cell lung cancer (NSCLC). The 5-year survival rate of patients with NSCLC is about 16% with current treatments including surgery, radiation and other classic chemotherapeutic agents and targeted...